Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide plus Chemoimmunotherapy in Relapsed/Refractory Neuroblastoma
NCT07437963Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2027
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide in neuroblastoma, ganglioneuroblastoma (GNB), sponsored by National Cancer Institute. Planned start Jun 2027; status: recruiting.
02
Drugs
iberdomide
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT07437963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437963.